Key statistics dashboard for Aclaris Therapeutics, Inc. (ACRS). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions.
Stock Data
| Price | $5.32 |
| Market Cap | $743M |
| Enterprise Value | $723.8M |
| Beta | 0.68 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -9.17 |
| Price / Book | 6.10 |
| P/S | 90.40 |
| EV/EBITDA | -9.64 |
| EV/Sales | 88.07 |
| EV/FCF | -11.64 |
| P/FCF | -11.95 |
| Earnings Yield | -9.97% |
| FCF Yield | -8.37% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 95.61% |
| EBIT Margin | -921.50% |
| EBITDA Margin | -913.92% |
| Operating Margin | -1050.16% |
| Net Margin | -921.50% |
| Return on Equity | -61.65% |
| Return on Assets | -42.15% |
| Return on Invested Capital | -56.99% |
| Return on Capital Employed | -56.99% |
Financial Health
| Current Ratio | 3.46 |
| Quick Ratio | 3.46 |
| Cash Ratio | 0.68 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Net Debt / EBITDA | 0.26 |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -5.19 |
Per-Share Data
| Revenue per share | 0.06 |
| Book Value per share | 0.87 |
| Cash per share | 0.64 |
| FCF per share | -0.44 |
| Tangible Book Value per share | 0.87 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 13 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 16 |
| Avg rating (1-5) | 0.81 |
Related companies: ALLO · BIOA · CABA · EDIT · MASS · MDXH · NEO
Explore sector: Healthcare · Biotechnology
More sections of ACRS: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks